Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea
NDA submission supported by positive Phase 3 clinical data
Related news for (DERM)
- Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
- Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
- Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
- Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights